For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- RaQualia Ties Up with Eli Lilly for Pain Treatments
January 10, 2011
- Need to Reduce the Number of Generics Pointed Out at Chuikyo
January 10, 2011
- METI's Life Innovation-Related Budgets Down ¥230 Mil. to ¥8,280 Mil.
January 10, 2011
- Korosho to Support First-in-Human Trials in Earnest
January 10, 2011
- Research Spending down 7.9% to ¥1,193.7 Bil. for Pharma Industry in FY2009
January 10, 2011
- Hospira Japan to Begin Development of Biosimilars in Japan
January 10, 2011
- Korosho Obliged to Make a Sensitive Decision on Actos Generics
January 10, 2011
- NIBIO Identifies Structure of TNF-TNFR2 Complex
January 10, 2011
- Wakunaga Signs an MTA with A-CUBE for Therapeutic MABs
January 10, 2011
- Velcade Approved for Naive MM Patients
January 10, 2011
- DSP, Chugai to Jointly Develop MDS Vaccine
January 10, 2011
- Kyorin Refuses Sawai Further Explanations
January 10, 2011
- Lunabell Approved for Functional Dysmenorrhea
January 10, 2011
- Takeda Signs Anti-Obesity Drug Discovery Partnership Agreement
January 10, 2011
- ViiV Reduces Operation Costs Utilizing GSK's Business Resources
January 10, 2011
- Daiichi Sankyo's Sevikar HCT Approved in Germany
January 10, 2011
- Fulvestrant Better Controls Breast Cancer than Anastrozole: AZ
January 10, 2011
- Wholesalers' Services Cost-Effective in Japan: FJPWA Report
January 10, 2011
- FDA Approves Merck's Gardasil for Anal Cancer
January 10, 2011
- Prospects for Simultaneous Global Development: 2
January 10, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…